依达拉奉治疗急性大面积脑梗死的疗效观察

目的 观察依达拉奉治疗急性大面积脑梗死(ALACI)的临床疗效.方法 选择发病72 h内的ALACI患者31例,随机分为依达拉奉组(观察组)16例和对照组15例.观察组应用依达拉奉静脉滴注,剂量为30 mg,2次/d,14 d为1个疗程,余治疗与对照组相同.在治疗前、治疗后7、14、21 d对患者进行中国脑卒中临床神经功能缺损评分量表(CSS)及日常生活能力(ADL)的测定.结果 观察组治疗后7 d和14 d CSS及ADL评分均较对照组治疗前减少,差异有统计学意义(P<0.05);治疗后21 d明显减少,差异有统计学意义(P<0.01).观察组无明显不良反应.结论 依达拉奉能有效改善急性大面积脑梗死患者的神经功能缺失、日常生活能力,无明显不良反应.

The curative effect study of edaravone on patients with acute lagre areacerebellar infarction

Objective To observe the clinical curative effect of edaravone on treatment of acute lagre area cerebellar irdarction(ALACI). Methods 31 ALACI patients attacked within 72h were randomly assigned to therapygroup( n = 16) and control group( n = 15). Therapy group took the basic treatment as well as edaravone infused at a dose of 30mg,twice a day for 14 days. Control group took similar treatment to therapy group expect for edaravone.At 0th ,7th, 14th ,21th day after treatment, the C.SS and ability of daily living(ADL) were used to evaluate the recovery of neurological functions. Results Significant difference of CSS and ADL grading were detected between therapygoup and control group at 7th, 14th day( P < 0.05 ), with lower grading in therapy group ; there were significant differ-ence of CSS and ADL grading between therapy goup and control group at 21th day( P < 0.01 ), with lower grading in therapy group. No evident side effect was detected in edaravone therapy group. Conclusion Edaravone is a safe a-gent. It can effectively improve the neurological deficits and daily living ability of ALACI patients.